Kuros Biosciences Ltd.

Board/Management Information • Mar 4, 2010

News Details

Corporate | 4 March 2010 17:35

Cytos Biotechnology Ltd: Dr. Thomas Hecht succeeds Dr. François L’Eplattenier as chairman of the Board of Directors

Cytos Biotechnology AG / Change of Personnel

04.03.2010 17:35

Dissemination of a Corporate News, transmitted by
DGAP - a company of EquityStory AG.
The issuer / publisher is solely responsible for the content of this announcement.

---

Schlieren (Zurich), Switzerland, March 4, 2010 - Cytos Biotechnology Ltd
(SIX:CYTN) informs that the Board of Directors of Cytos Biotechnology Ltd
decided at today's meeting that Dr. Thomas Hecht (59), presently
vice-chairman, will succeed Dr. François L'Eplattenier (70) as chairman of
the Board of Directors as of the next Shareholders' Meeting on April 22,
2010 as already communicated on February 3rd, 2010. Dr. François
L'Eplattenier whose three year term is completed at the next shareholders'
meeting will not stand for re-election due to age. Dr. Thorlef Spickschen
(69) will become vice-chairman.

About Cytos Biotechnology

Cytos Biotechnology Ltd is a public Swiss biotechnology company that
specializes in the discovery, development and commercialization of a new
class of biopharmaceutical products - the Immunodrugs(TM). Immunodrugs(TM)
are intended for use in the treatment and prevention of common chronic
diseases, which afflict millions of people worldwide. Immunodrugs(TM) are
designed to instruct the patient's immune system to produce desired
therapeutic antibody or T cell responses that modulate chronic disease
processes. Taking advantage of the high flexibility of its Immunodrug(TM)
platform, Cytos Biotechnology has built a diversified pipeline of
Immunodrug(TM) candidates in various disease areas, of which six are
currently in clinical development. The Immunodrug(TM) candidates are
developed both in-house and together with Novartis, Pfizer and Pfizer
Animal Health. Founded in 1995 as a spinoff from the Swiss Federal
Institute of Technology (ETH) in Zurich, the Company is located in
Schlieren (Zurich). Currently, the Company has 83 full-time employees.
Cytos Biotechnology Ltd is listed on the SIX Swiss Exchange (SIX:CYTN).

This foregoing press release may contain forward-looking statements that
include words or phrases such as 'intended', or other similar expressions.
These forward-looking statements are subject to a variety of significant
uncertainties, including scientific, business, economic and financial
factors, and therefore actual results may differ significantly from those
presented. There can be no assurance that any further therapeutic entities
will enter clinical trials, that clinical trial results will be predictive
for future results, that therapeutic entities will be the subject of
filings for regulatory approval, that any drug candidates will receive
marketing approval from the U.S. Food and Drug Administration or equivalent
regulatory authorities, or that drugs will be marketed successfully.
Against the background of these uncertainties readers should not rely on
forward-looking statements. The company assumes no responsibility to update
forward-looking statements or adapt them to future events or developments.
This document does not constitute an offer or invitation to subscribe or

Wolfgang A. Renner, PhD
Chief Executive Officer
Cytos Biotechnology Ltd
Phone: +41 44 733 47 03
Fax: +41 44 733 47 04
e-Mail: wolfgang.renner@cytos.com
Website: www.cytos.com

04.03.2010 Ad hoc announcement, Financial News and Media Release distributed by DGAP.
Media archive at www.dgap-medientreff.de and www.dgap.de

---

Language: English
Company: Cytos Biotechnology AG
Wagistr. 25
8952 Schlieren
Schweiz
Phone: +41 44 733 4747
Fax: +41 44 733 4740
E-mail: info@cytos.com
Internet: www.cytos.com
ISIN: CH0011025217, CH0029060735
WKN: -
Listed: Freiverkehr in Berlin, München, Stuttgart; Open Market in
Frankfurt; Foreign Exchange(s) SIX

End of News DGAP News-Service

---